摘要
目的研究肝动脉化疗栓塞术（TACE）联合深部热疗治疗晚期原发性肝癌的临床疗效及不良反应。方法2010年6月-2013年7月收治的Ⅲ-V期原发性肝癌患者62例随机分为治疗组和对照组。治疗组31例接受TACE联合深部热疗治疗,对照组31例接收单纯TACE治疗。随访1年,记录治疗经过、治疗前后肿瘤大小、肿瘤标志物甲胎蛋白（AFP）、Karnofsky评分（KPS）,观察并记录患者总生存期。结果经过综合治疗,治疗组的肿瘤控制有效率为67.7%,而对照组仅为38.7%,治疗组明显高于对照组（P〈0.05）。治疗组AFP从治疗前的（178.27±21.46）ng/ml下降至治疗后的（92.88±22.06）ng/ml,对照组AFP从治疗前的（170.32±19.38）ng/ml下降至治疗后的（163.85±20.41）ng/ml,治疗组优于对照组（P〈0.05）。治疗组KPS评分由治疗前的（61.67±8.57）分升高至（82.22±7.32）分,对照组由治疗前的（65.38±7.92）分升高至（71.89±8.14）分,治疗组升高明显高于对照组,2组差异有统计学意义（P〈0.05）。治疗组患者中位生存时间10个月,3个月、6个月、9个月和1年的总生存率分别为96.8%、87.1%、61.3%和41.9%,对照组患者中位生存时间8.7个月,3个月、6个月、9个月和1年的总生存率分别为87.1%、54.8%、45.2%和29.0%,治疗组在延长患者总生存期方面明显优于对照组（P=0.006）。结论TACE联合深部热疗治疗晚期原发性肝癌安全有效,可以显著缩小肿瘤,改善患者生活质量,延长生存时间。
Objective To study the clinical effect and adverse reaction of hepatic transcatheter arterial chemoemboli-zation （ TACE） combined with hyperthermia in the treatment of advanced primary liver cancer. Methods From 2010 June to 2013 July, 62 cases of primary liver cancer patients in stage III-IV were randomly divided into treatment group and control group. The treatment group with 31 patients received TACE combined with hyperthermia treatment, the control group with 31 cases received TACE therapy alone. 1 years of follow-up after treatment, before and after treatment, tumor size, tumor index alpha fetal protein （ AFP） , Karnofsky score （ KPS） were recorded, and the patients＆#39; overall survival were observed and recor-ded. Results After the comprehensive treatment, the treatment group＇s tumor control rate was 67. 7%, and 38. 7% in the control group, the treatment group＇s tumor control rate was significantly higher than that of the control group （ P 〈0. 05）. The treatment group＇s AFP from before treatment （178. 27 ± 21. 46） ng/ml decreased to after treatment （92. 88 ± 22. 06） ng/ml, control group AFP from before treatment （170. 32 ± 19. 38） ng/ml decreased to after treatment （163. 85 ± 20. 41） ng/ml, the treatment group＇s results better than that in control group （ P 〈0. 05）. The treatment group＇s KPS score from before treatment （61. 67 ± 8. 57） points increased to （82. 22 ± 7. 32） points, the control group from before treatment of the （65. 38 ± 7. 92） points increased to （71. 89 ± 8. 14） points, the treatment group＇s results were better than that of control group, there was sig-nificant difference between the 2 groups （ P 〈0. 05）. Treatment group＇s medium survival time was 10 months, 3 months, 6 months, 9 months and 1 year＇s overall survival rates in the treatment group were 96. 8%, 87. 1%, 61. 3% and 41. 9%, the medium survival time was 8. 7 months in control group, 3 months, 6 months, 9 months and 1 year＇s overall survival r
出处
《疑难病杂志》
CAS
2015年第2期154-157,共4页
Chinese Journal of Difficult and Complicated Cases
基金
2014年番禺区科技计划项目(No.2014-Z03-47)
关键词
肝动脉化疗栓塞术
深部热疗
肝癌
原发性
临床研究
Transcatheter arterial chemoembolization
Hyperthermia treatment
Liver cancer,primary
Clinical study
